百克生物：公司构建了以“升级换代、填补空白、创新突破”为方向的梯队式研发策略

Core Viewpoint - The company emphasizes innovation in product research and development as the driving force for growth, supported by over 20 years of technological expertise and a well-structured, multi-faceted R&D pipeline [1] Group 1: R&D Strategy - The company has established a tiered R&D strategy focused on "upgrading, filling gaps, and innovative breakthroughs" [1] - A robust development model has been created, consisting of "production generation, R&D generation, and reserve generation" to ensure steady progress in R&D strategies [1] Group 2: Technology Platforms - The company has built five core technology platforms: "virus large-scale culture technology platform," "formulation and adjuvant technology platform," "gene engineering technology platform," "bacterial vaccine technology platform," and "mRNA vaccine technology platform" [1] - The R&D pipeline includes 13 vaccine projects and 3 monoclonal antibodies related to infectious disease prevention [1] Group 3: Product Development Milestones - By 2025, the company expects to achieve significant milestones in R&D, including obtaining production approval for a liquid nasal spray influenza vaccine and clinical approvals for five other vaccines, including a recombinant shingles vaccine [1] Group 4: Company Mission and Goals - The company is committed to "biotechnology for a healthy future" and aims to be a first-class enterprise producing first-class products while nurturing top talent [1] - Continuous improvement of the pipeline layout and differentiation in products are seen as key to winning market share and providing a solid foundation for high-quality development [1]